FDA Approval Decisions Changing In Light Of Relabeling Failures - Woodcock
Executive Summary
FDA is not approving some prescription drugs because of a lack of confidence in labeling restrictions to ensure appropriate prescribing behavior, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said during a National Public Radio interview Dec. 19.
You may also be interested in...
FDA Handling Of Antidepressant Inquiry “Troubles” Senate Investigators
The Senate Finance Committee is asking for contact information for former employees of FDA's Office of Drug Safety in its continuing investigation into the agency's handling of information on a possible link between antidepressants and suicide
FDA Handling Of Antidepressant Inquiry “Troubles” Senate Investigators
The Senate Finance Committee is asking for contact information for former employees of FDA's Office of Drug Safety in its continuing investigation into the agency's handling of information on a possible link between antidepressants and suicide
Phase IV Commitments For Registries Likely To Increase, Genentech Says
Manufacturers should expect more postmarketing commitments for safety and pregnancy exposure registries for chronic disease medications, Genentech Senior Epidemiologist Haley Kaplowitz, PhD, said during the Drug Information Association conference on pharmacovigilance in Washington, D.C. Jan. 14